	US 12,171,734 B2
	Pathogenic bacteria
Simon Cutting, London (GB); and Hong Huynh, London (GB)
Assigned to Sporegen Limited, London (GB)
Appl. No. 16/970,708
Filed by Sporegen Limited, London (GB)
PCT Filed Feb. 15, 2019, PCT No. PCT/GB2019/050409 § 371(c)(1), (2) Date Aug. 18, 2020, PCT Pub. No. WO2019/162652, PCT Pub. Date Aug. 29, 2019.
Claims priority of application No. 1802720 (GB), filed on Feb. 20, 2018.
Prior Publication US 2020/0375931 A1, Dec. 3, 2020
Int. Cl. A61K 31/195 (2006.01); A23L 33/10 (2016.01); A61K 9/107 (2006.01); A61K 38/12 (2006.01); A61P 31/04 (2006.01)

CPC A61K 31/195 (2013.01) [A23L 33/127 (2016.08); A61K 9/107 (2013.01); A61K 38/12 (2013.01); A61P 31/04 (2018.01); A23V 2002/00 (2013.01)]

36 Claims

1. An antibiotic composition comprising precipitated micelles comprising: (i) an antibiotic, wherein the antibiotic is Chlorotetaine, and (ii) a lipopeptide selected from the group consisting of a member of the Surfactin family, a member of the Iturin family and a member of the Fengycin family, wherein the lipopeptide facilitates the formation of micelles, and wherein the micelle incorporates or absorbs the antibiotic.